Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm

Background AVAGAST was an international, randomized, placebo-controlled phase III study of chemotherapy with or without bevacizumabas first-line therapy for patients with advanced gastric cancer. We performed exploratory analyses to evaluate regional differences observed in the trial.